ReviewCells2021
Role of ADGRG1/GPR56 in Tumor Progression.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Adhesion GPCR-induced ectocytosis mediates intercellular GPCR signal propagation.Nature chemical biology · 2026Article
- Article
- ADGRF4 and ADGRL4 as novel prognostic biomarkers and potential therapeutic implications in stomach adenocarcinoma.BMC gastroenterology · 2026Article
- Adhesion G protein-coupled receptors.Pharmacological reviews · 2026Review
- The Role of the TG2-GPR56 Complex in Cutaneous Squamous Cell Carcinoma (CSCC) Aggression and Therapeutic Resistance.International journal of molecular sciences · 2026Review
- CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis.Journal for immunotherapy of cancer · 2026Article
- Multiplex Immune Profiling Reveals the Role of Serum Immune Proteomics in Predicting Response to Radioiodine after Total Resection of Papillary Thyroid Carcinoma.Journal of proteome research · 2026Article
- ADGRD1 promotes bladder cancer progression and angiogenesis via the PI3K/AKT/mTOR-mediated pro-angiogenic secretome.Frontiers in oncology · 2026Article
- Receptor Co‑targeting Strategies for Personalized Ovarian Cancer Therapy.International journal of nanomedicine · 2026Review
- Proliferation-cycle gene signatures predict immune landscape and prognosis in lung adenocarcinoma.Discover oncology · 2025Article
- Plasma proteomics to explore benefit from anti-PD-(L)1 in advanced solid tumors: a prospective pilot study.Scientific reports · 2025Article
- GPR56/ADGRG1 induces biased Rho-ROCK-MLC and JAK-STAT3 signaling to promote amoeboid-like morphology and IL-6 upregulation in melanoma cells.Cell communication and signaling : CCS · 2025Article
- Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy.Journal for immunotherapy of cancer · 2025Article
- GPR56 facilitates hepatocellular carcinoma metastasis by promoting the TGF-β signaling pathway.Cell death & disease · 2024Article
- Role of G protein coupled receptors in acute kidney injury.Cell communication and signaling : CCS · 2024Review
- G protein coupled receptor in apoptosis and apoptotic cell clearance.FASEB bioAdvances · 2024Review
- A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer.Breast cancer research and treatment · 2024Article
- Former smoking associated with epigenetic modifications in human granulosa cells among women undergoing assisted reproduction.Scientific reports · 2024Article
- GPR56, an Adhesion GPCR with Multiple Roles in Human Diseases, Current Status and Future Perspective.Current drug targets · 2024Review
- Identification of biomarkers for tumor regression grade in esophageal squamous cell carcinoma patients after neoadjuvant chemoradiotherapy.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular communication plays a critical role in diverse aspects of tumorigenesis including tumor cell growth/death, adhesion/detachment, migration/invasion, angiogenesis, and metastasis. G protein-coupled receptors (GPCRs) which constitute the largest group of cell surface receptors are known to play fundamental roles in all these processes. When considering the importance of GPCRs in tumorigenesis, the adhesion GPCRs (aGPCRs) are unique due to their hybrid structural organization of a long extracellular cell-adhesive domain and a seven-transmembrane signaling domain. Indeed, aGPCRs have been increasingly shown to be associated with tumor development by participating in tumor cell interaction and signaling. ADGRG1/GPR56, a representative tumor-associated aGPCR, is recognized as a potential biomarker/prognostic factor of specific cancer types with both tumor-suppressive and tumor-promoting functions. We summarize herein the latest findings of the role of ADGRG1/GPR56 in tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.